| DC46949 |
Terevalefim
|
Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor. |
| DC46948 |
Gemnelatinib
|
Gemnelatinib is a tyrosine kinase inhibitor (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer. |
| DC46947 |
Fosgonimeton
|
Fosgonimeton is a hepatocyte growth factor receptor agonist (WO2017210489). |
| DC44838 |
Norleual
|
Norleual is an angiotensin IV analog. Norleual is a highly potent HGF/c-MET inhibitor (IC50=3 pM). Norleual inhibits HGF-induced MDCK cell proliferation and invasion in vitro. Norleual also is an AT4 receptor antagonist; disrupts LTP stabilization. Antiangiogenic. |
| DC39099 |
Ningetinib
|
Ningetinib is a potent, orally bioavailable inhibitor of tyrosine kinase with IC50 of 6.7 nM, 1.9 nM and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib exhibits antitumor activity. |
| DC28340 |
BPI-9016M
|
BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma. |
| DC8515 |
BMS-2
|
BMS-2 is a potent MET kinase inhibitor with an IC50 value of 1.8nM. It also possesses potent inhibitory activity against Flt-3 and VEGFR-2 kinases, IC50 values of 4nM and 27nM respectively. |
| DC12007 |
SOMG-833
|
A potent, selective, ATP-competitive c-MET inhibitor with IC50 of 0.93 nM. |
